Evidence map›Paper›PMID 41668712›Full record

ArticleBiomedical reports2026

Exploratory transcriptomics and

Wataru Kakuguchi, Masahiro Morimoto, Kenta Takahashi, Nako Maishi, Kyoko Hida, Takao Nomura, Satoko Otsuguro, Katsumi Maenaka, Yoichi Ohiro

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedical reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wataru KakuguchiDepartment of Oral and Maxillofacial Surgery, Division of Oral Pathobiological Science, Faculty of Dental Medicine and Graduate School of Dental Medicine, Hokkaido University, Sapporo, Hokkaido 060-8586, Japan.
Masahiro MorimotoDivision of Head and Neck, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
Kenta TakahashiDepartment of Oral and Maxillofacial Surgery, Division of Oral Pathobiological Science, Faculty of Dental Medicine and Graduate School of Dental Medicine, Hokkaido University, Sapporo, Hokkaido 060-8586, Japan.
Nako MaishiDepartment of Vascular Biology and Molecular Pathology, Division of Oral Pathobiological Science, Faculty of Dental Medicine and Graduate School of Dental Medicine, Hokkaido University, Sapporo, Hokkaido 060-8586, Japan.
Kyoko HidaDepartment of Vascular Biology and Molecular Pathology, Division of Oral Pathobiological Science, Faculty of Dental Medicine and Graduate School of Dental Medicine, Hokkaido University, Sapporo, Hokkaido 060-8586, Japan.
Takao NomuraCenter for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Hokkaido 060-0812, Japan.
Satoko OtsuguroCenter for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Hokkaido 060-0812, Japan.
Katsumi MaenakaCenter for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Hokkaido 060-0812, Japan.
Yoichi OhiroDepartment of Oral and Maxillofacial Surgery, Division of Oral Pathobiological Science, Faculty of Dental Medicine and Graduate School of Dental Medicine, Hokkaido University, Sapporo, Hokkaido 060-8586, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Suramin, an anti-trypanosomal agent, has gained attention for its potential anticancer activity, partly through the modulation of RNA-binding proteins such as HuR. However, its genome-wide transcriptomic effects in oral squamous cell carcinoma remain unclear. In the present study, RNA-sequencing was performed on suramin-treated HSC-3 cells, followed by enrichment, network and transcription factor analyses.

Indexed as

cell cycleorthotopic mouse modelsuramintongue squamous cell carcinomatranscriptomics

Identifiers

PMID41668712
PMCPMC12884683

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.